Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may reveal hidden clues to hair loss severity

NCT ID NCT07733063

Knowledge-focused Sponsor: Istanbul Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study investigates whether two substances in the blood—GPX4 and MDA—are linked to the severity of alopecia areata, a condition that causes patchy hair loss. Researchers will compare levels of these markers in 104 people with alopecia areata and 52 healthy volunteers. The goal is to see if these markers can serve as objective tools to monitor disease activity and hair loss progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If certain blood markers are linked to disease severity, doctors may have a simple way to monitor alopecia areata and guide treatment.
What could go wrong
This is an observational study, not a treatment trial. It may find no clear link between the markers and hair loss severity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 156 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will be selected from patients who present to the Department of Dermatology at Istanbul Training and Research Hospital and meet all the eligibility criteria. The sample will consist of two primary groups: a patient group diagnosed with Alopecia Areata (further stratified into acute and chronic cohorts based on disease activity and duration) and an age- and sex-matched healthy control group comprised of volunteers with no prior history of alopecia or systemic disease.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged between 18 and 65 years. * Formally diagnosed with Alopecia Areata based on clinical and trichoscopic examination. * Healthy volunteers with no personal or family history of alopecia or any systemic inflammatory/autoimmune conditions (for the healthy control group). * Patients who have provided written informed consent before any study-related procedures. Exclusion Criteria: * Use of topical corticosteroids, intralesional steroid injections, or topical calcineurin inhibitors within the last 1 month. * Use of systemic immunosuppressive therapies, systemic corticosteroids, or JAK inhibitors within the last 3 months. * Presence of any other co-existing active autoimmune or inflammatory skin diseases (e.g., Psoriasis, Vitiligo, or active autoimmune thyroiditis with elevated TSH levels). * History of malignancy, active severe infection, chronic hepatic failure, or chronic renal failure. * Pregnancy or lactation. * History of heavy smoking or uncontrolled/regular use of antioxidant or vitamin supplements (e.g., Vitamin E, Vitamin C, CoQ10, NMN, resveratrol).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia Alopecia areata Alopecia areata (& ophiasis) Alopecia areata(AA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istanbul Training and Research Hospital, Department of Dermatology

    RECRUITING

    Istanbul, Cerrahpasa Mahallesi, 34098, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.